gemtuzumab ozogamicin

Trials studying gemtuzumab ozogamicin

• phase3Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)recruitingn=130
• phase2A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemiasuspendedn=70
• phase1CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLrecruitingn=18
• phase2Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemiarecruitingn=36
• phase2A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AMLactive not recruitingn=19
• phase2Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSterminatedn=67
• phase1Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113completedn=18
• phase2Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapycompletedn=16